Investors pile into CANbridge stock but can the rally last?
The maker of drugs for rare diseases has enjoyed an explosive rise in its share price, helped by a partnership deal and Chinese moves to widen access to costly therapies…
B&K Corp eyes IPO to keep its slow-developing drugs alive
The company focuses on wound-healing PDGF drugs and its core product, Pro-101-2, isn’t expected to enter Phase 3 clinical trials for at least three more years Key Takeaways: B&K lost…
Jiangsu Recbio Shoots to Become Hong Kong’s First HPV Vaccine Stock
The vaccine producer is making a second attempt to list in Hong Kong, as its core HPV vaccine undergoes Phase 3 clinical trials Key takeaways: Jiangsu Recbio has filed a…
RELATED ARTICLES
-
No respite for RemeGen as problems and losses pile up
9995.HK 688331.SHG -
JL Mag fortified by strategic status of rare earths in U.S.-China trade war
6680.HK 300748.SHE
- RNA drug developer Ribo Life targets fresh funding channel
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
Airdoc Tech enjoys healing properties of medical AI rally
2251.HK
-
3SBio hits the big time with $6 billion cancer drug deal
1530.HK
-
Kintor Pharma shifts from cancer drugs to cosmetics as funds run low
9939.HK
